Join Growin Stock Community!

Liminatus pharma, inc. warrantsLIMNW.US Overview

US StockHealthcare
(No presentation for LIMNW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LIMNW AI Insights

LIMNW Overall Performance

LIMNW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LIMNW Recent Performance

-20.47%

Liminatus pharma, inc. warrants

0.05%

Avg of Sector

-0.31%

S&P500

LIMNW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LIMNW Key Information

LIMNW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LIMNW Profile

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Price of LIMNW

LIMNW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LIMNW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1

No related data records

  • When is LIMNW's latest earnings report released?

    The most recent financial report for Liminatus pharma, inc. warrants (LIMNW) covers the period of 2024Q1 and was published on 2024/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LIMNW's short-term business performance and financial health. For the latest updates on LIMNW's earnings releases, visit this page regularly.

  • How much cash does LIMNW have?

    At the end of the period, Liminatus pharma, inc. warrants (LIMNW) held Total Cash and Cash Equivalents of 804.54K, accounting for 0.28 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.